0.8156
price down icon7.32%   -0.0644
after-market アフターアワーズ: .82 0.0044 +0.54%
loading
前日終値:
$0.88
開ける:
$0.8699
24時間の取引高:
1.17M
Relative Volume:
1.71
時価総額:
$38.12M
収益:
-
当期純損益:
$-37.65M
株価収益率:
-0.4884
EPS:
-1.67
ネットキャッシュフロー:
$-24.14M
1週間 パフォーマンス:
-25.85%
1か月 パフォーマンス:
-5.92%
6か月 パフォーマンス:
-30.88%
1年 パフォーマンス:
-45.63%
1日の値動き範囲:
Value
$0.7888
$0.8699
1週間の範囲:
Value
$0.7888
$1.1499
52週間の値動き範囲:
Value
$0.485
$4.28

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile

Name
名前
Reviva Pharmaceuticals Holdings Inc
Name
セクター
Healthcare (1169)
Name
電話
(408) 501-8881
Name
住所
10080 N WOLFE ROAD, CUPERTINO
Name
職員
14
Name
Twitter
Name
次回の収益日
2025-03-31
Name
最新のSEC提出書
Name
RVPH's Discussions on Twitter

RVPH を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RVPH
Reviva Pharmaceuticals Holdings Inc
0.8156 51.41M 0 -37.65M -24.14M -1.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
251.72 25.78B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
446.48 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3401 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.81 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
487.86 65.13B 14.09B 4.50B 2.96B 39.28

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-09-20 開始されました ROTH MKM Buy
2023-06-08 開始されました The Benchmark Company Speculative Buy
2022-01-24 開始されました H.C. Wainwright Buy

Reviva Pharmaceuticals Holdings Inc (RVPH) 最新ニュース

pulisher
02:33 AM

Reviva reports positive year-long schizophrenia drug study By Investing.com - Investing.com South Africa

02:33 AM
pulisher
Jun 02, 2025

Reviva Pharmaceuticals Holdings, Inc. Announces Positive Full Dataset for 1-Year Phase 3 Recover Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva Reports Positive Full Dataset For Phase 3 RECOVER OLE Study Of Brilaroxazine In Schizophrenia - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva reports positive year-long schizophrenia drug study - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva Pharmaceuticals (RVPH) Unveils Promising Phase 3 Brilaroxazine Study Results | RVPH Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva Pharmaceuticals Completes Phase 3 Study for Schizophrenia - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva Announces Positive Full Dataset for 1-Year Phase 3 - GlobeNewswire

Jun 02, 2025
pulisher
May 31, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Shares Sold by Millennium Management LLC - Defense World

May 31, 2025
pulisher
May 30, 2025

Reviva Pharmaceuticals Launches $50M At-Market Offering - TipRanks

May 30, 2025
pulisher
May 30, 2025

Reviva Pharmaceuticals Holdings IncEnters Into At Market Issuance Sales AgreementSEC Filing - marketscreener.com

May 30, 2025
pulisher
May 26, 2025

What is Zacks Small Cap’s Estimate for RVPH Q2 Earnings? - Defense World

May 26, 2025
pulisher
May 23, 2025

Roth Capital Issues Positive Forecast for RVPH Earnings - Defense World

May 23, 2025
pulisher
May 22, 2025

D. Boral Capital Lowers Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target to $3.00 - Defense World

May 22, 2025
pulisher
May 20, 2025

Reviva Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks

May 20, 2025
pulisher
May 20, 2025

Reviva stock target cut to $3 on cash concerns, retains Buy rating - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Spotify To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday - NewsBreak: Local News & Alerts

May 20, 2025
pulisher
May 20, 2025

Reviva to Participate in Upcoming Investor Conferences in May 2025 - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Late-Stage CNS Drug Developer Reviva Opens Access to Management at Benchmark and Lytham Conferences - Stock Titan

May 20, 2025
pulisher
May 20, 2025

Reviva Pharmaceuticals (RVPH): Analyst Maintains Buy Rating, Low - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Reviva Pharmaceuticals (RVPH) Sees Price Target Reduction Amid Funding Concerns | RVPH Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Reviva Pharmaceuticals (RVPH): Analyst Maintains Buy Rating, Lowers Price Target | RVPH Stock News - GuruFocus

May 20, 2025
pulisher
May 16, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Buy” from Brokerages - Defense World

May 16, 2025
pulisher
May 15, 2025

Reviva Pharmaceuticals (RVPH) Advances Brilaroxazine Program Tow - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Reviva Pharmaceuticals (RVPH) Advances Brilaroxazine Program Towards Approval | RVPH Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times

May 15, 2025
pulisher
May 15, 2025

Major Milestone: 446 Patients Complete Reviva's Schizophrenia Drug Trial, Full Results Expected Q2 2025 - Stock Titan

May 15, 2025
pulisher
May 13, 2025

Reviva to Participate in the A.G.P. Healthcare Company Showcase - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Tower Research Capital LLC TRC Has $48,000 Stock Holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World

May 13, 2025
pulisher
May 11, 2025

Reviva Pharmaceuticals (RVPH) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 04, 2025

Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Grows By 30.5% - Defense World

May 04, 2025
pulisher
May 03, 2025

Geode Capital Management LLC Grows Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World

May 03, 2025
pulisher
May 01, 2025

Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight - GlobeNewswire Inc.

May 01, 2025
pulisher
Apr 29, 2025

Reviva to Participate in the Citizens Life Sciences Conference - GlobeNewswire

Apr 29, 2025
pulisher
Apr 29, 2025

Reviva Pharma CEO Takes Center Stage: Key Updates Coming at Major Life Sciences Conference - Stock Titan

Apr 29, 2025
pulisher
Apr 28, 2025

Gaining Ground: Reviva Pharmaceuticals Holdings Inc (RVPH) Closes Lower at 0.86, Down -4.98 - DWinneX

Apr 28, 2025
pulisher
Apr 28, 2025

Market Update: American Rebel Holdings Inc (AREB) Sees Negative Movement, Closing at 3.85 - DWinneX

Apr 28, 2025
pulisher
Apr 27, 2025

Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 26, 2025

D. Boral Capital Reiterates “Buy” Rating for Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World

Apr 26, 2025
pulisher
Apr 24, 2025

Reviva Pharmaceuticals Holdings Inc Inc. (RVPH) Price Performance: The Role of Supply and Demand - investchronicle.com

Apr 24, 2025
pulisher
Apr 24, 2025

Reviva to Present Late-Breaking Poster on the RECOVER - GlobeNewswire

Apr 24, 2025
pulisher
Apr 24, 2025

Major Phase 3 Breakthrough: Reviva Unveils 12-Month Schizophrenia Treatment Data at ASCP 2025 - Stock Titan

Apr 24, 2025
pulisher
Apr 24, 2025

Investing in Reviva Pharmaceuticals Holdings Inc (RVPH) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com

Apr 24, 2025
pulisher
Apr 21, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Apr 21, 2025
pulisher
Apr 19, 2025

Reviva Pharmaceuticals (RVPH) to Release Earnings on Monday - Defense World

Apr 19, 2025
pulisher
Apr 07, 2025

RVPH: M&A Deals Highlight Brilaroxazine Value - MSN

Apr 07, 2025
pulisher
Apr 07, 2025

What is Roth Capital’s Forecast for RVPH Q1 Earnings? - Defense World

Apr 07, 2025
pulisher
Apr 04, 2025

Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results - streetwisereports.com

Apr 04, 2025
pulisher
Apr 03, 2025

Reviva Pharmaceuticals Holdings Inc. (RVPH) reports earnings - qz.com

Apr 03, 2025
pulisher
Apr 02, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target Lowered to $8.00 at D. Boral Capital - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Reviva Pharmaceuticals Reports 2024 Financial Results - TipRanks

Apr 02, 2025
pulisher
Apr 01, 2025

RVPH stock touches 52-week low at $0.6 amid market challenges - Investing.com Australia

Apr 01, 2025

Reviva Pharmaceuticals Holdings Inc (RVPH) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.16
price up icon 0.87%
$31.13
price down icon 0.19%
$576.61
price down icon 1.37%
$303.77
price down icon 0.76%
$4.5807
price down icon 0.41%
$487.86
price down icon 0.60%
大文字化:     |  ボリューム (24 時間):